IGS01

Primary Objectives: SAD Trial Part: To evaluate the safety of a single oral dose of IGS01 and to explore the maximum tolerated dose in healthy adult participants. MAD Trial Part: To evaluate the safety and tolerability of multiple oral doses of IGS01 in healthy adult participants. Secondary Objectives: SAD Trial Part: To evaluate the pharmacokinetic (PK) characteristics of IGS01 and its active metabolites after a single oral dose in healthy adult participants. To explore the effect of IGS01 on the QTc interval using a drug concentration-QTc interval model in healthy adult participants. MAD Trial Part: To evaluate the PK characteristics of IGS01 and its active metabolites after multiple oral doses in healthy adult participants. To explore the effect of multiple oral doses of IGS01 on extrapyramidal symptoms in healthy adult participants.